Incyte Corp (INCY)
NASDAQ:INCY
Want to see INCY full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.78Last Year’s EPS
1.57Same Quarter Last Year
Moderate Buy
Based on 19 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and substantial pipeline/regulatory progress: double‑digit top‑line growth (Q1 revenue +21%, net sales +20%), outsized core ex‑Jakafi growth (+63% YoY), multiple late‑stage programs and regulatory acceptances (povorcitinib, 989 EOP meeting, 734 Phase III) and leadership hires to support launches. Offsetting risks include elevated R&D/operating spend, a small safety review and administrative hold related to pneumonitis in the 734 program, and continued revenue concentration in Jakafi. On balance the positives—robust revenue growth, core business acceleration, and clear late‑stage catalysts—outweigh the lowlights, though execution and safety monitoring remain important near‑term considerations.Company Guidance
Strong Top-Line Growth
Total revenue of $1.27B in Q1 2026, up 21% year-over-year; net sales $1.10B, up 20% YoY. Reaffirmed full-year 2026 net sales guidance of $4.77B–$4.94B (up ~10%–13% vs prior year).
Core Business Ex-Jakafi Accelerating
Core business excluding Jakafi grew 63% YoY. Opzelura sales $143M (up 20% YoY; U.S. $106M up 12%; International $37M up 56%). Hematology & oncology net sales grew 116% to $204M; notable contributors: Niktimvo $55M, Monjuvi $49M (up 67% YoY), Zynyz $41M.
Pipeline and Regulatory Momentum
Multiple regulatory and development milestones: FDA accepted NDA for povorcitinib in moderate–severe HS; positive Phase III vitiligo results supporting future submission; Jakafi XR on track for potential mid‑year approval/launch; Monjuvi first-line DLBCL submissions expected H1 with approval/launch anticipated early 2027; Phase III initiation for mutant CALR antibody 989 (ET) on track midyear; KRAS G12D program (734) Phase III initiated in first-line PDAC.
Compelling Late‑Stage Clinical Data for Povorcitinib
HS 54‑week data: HiSCR50 up to 71%, HiSCR75 up to 57%, HiSCR100 up to 29%; up to 20% achieved complete clearance of draining tunnels/nodules. Vitiligo Phase III: F‑VASI ≥75% primary endpoint met in two trials (n≈456 on 30 mg dose); T‑VASI50 improvements achieved. Safety profile over 52 weeks consistent with prior studies; TEAEs of special interest 2%–3%, no new safety signals reported.
Commercial and Management Readiness
Senior leadership appointments to support growth: new CFO Suky Upadhyay; Pablo Cagnoni named President & Global Head R&D; Steven Stein as CMO and Head of Late‑stage Development; Mohamed Issa as EVP Head of U.S. Commercial. U.S. commercial operations consolidated to create launch-ready organization (targeting multiple launches in 2026–2027).
Improving Operating Leverage and Stable Cost of Sales
GAAP R&D $516M (up 18% YoY) and GAAP SG&A $328M (up 1% YoY). Ongoing operating expenses increased 14% YoY vs ongoing revenues up 19% YoY, indicating improving operating leverage. Cost of sales expected to remain ~9% of net sales.
INCY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INCY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 28, 2026 | $95.72 | $97.74 | +2.12% |
Feb 10, 2026 | $109.03 | $100.05 | -8.24% |
Oct 28, 2025 | $93.08 | $91.65 | -1.54% |
Jul 29, 2025 | $70.16 | $77.38 | +10.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Incyte Corp (INCY) report earnings?
Incyte Corp (INCY) is schdueled to report earning on Aug 04, 2026, Before Open (Confirmed).
What is Incyte Corp (INCY) earnings time?
Incyte Corp (INCY) earnings time is at Aug 04, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INCY EPS forecast?
INCY EPS forecast for the fiscal quarter 2026 (Q2) is 1.78.